Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 23

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH

Alkhouri, Naim, LaCerte, Carl, Edwards, Jeffrey, Poordad, Fred, Lawitz, Eric, Lee, Lois, Karan, Sharon, Sawhney, Sangeeta, Erickson, Mary, MacConell, Leigh, Zaru, Luna, Chen, Jianfen, Campagna, Jason · 2024 · Liver International

Abstract

Background & Aims: Fibrosis stage is a strong predictor of nonalcoholic steatohepatitis (NASH) outcomes. Two blinded studies evaluated the pharmacokinetics, pharmacodynamics and safety of obeticholic acid (OCA) in subjects with staged NASH fibrosis or cirrhosis. Methods: Study 747‐117 randomized 51 subjects with NASH (fibrosis stages F1–F4) to daily placebo, OCA 10 or OCA 25 mg (1:2:2) for 85 days. Study 747‐118 randomized 24 subjects with NASH cirrhosis (F4; Child‐Pugh [CP]‐A) and normal liver control subjects matched for similar body weight to daily OCA 10 or OCA 25 mg (1:1) for 28 days. Individual and combined study data were analysed. Results: No severe or serious adverse events (AEs) or AEs leading to discontinuation or death occurred. Pruritus was the most frequent AE. Plasma OCA exposure (dose‐normalized area under the curve) increased with fibrosis stage but was a relatively poor predictor of hepatic OCA exposure (primary site of action), which remained constant across fibrosis stages F1–F3 and increased 1.8‐fold compared with F1 in subjects with cirrhosis due to NASH. Both cohorts showed robust changes in farnesoid X receptor activation markers with OCA treatment and marked decreases in alanine transaminase, aspartate transaminase and gamma‐glutamyltransferase. Conclusions: Despite higher drug exposures in subjects with NASH cirrhosis, short‐term daily treatment with OCA 10 or 25 mg was generally safe and well tolerated in subjects with NASH fibrosis or NASH CP‐A cirrhosis. Both cohorts experienced improvements in nonhistologic pharmacodynamic markers consistent with previously conducted OCA phase 2 and phase 3 studies in NASH fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.15816

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Combined study analyses: Steady-­ state dose-­ normalized plasma or liver total OCA exposure by fibrosis stage. (A) Plasma data are from Study 747-­ 117 and Study 747-­ 118 main study. (B) Liver data are from Study 747-­ 117 and Study 747-­ 118 hepatic PK substudy. Filled circles represent individual subject data. F, fibrosis stage; OCA, obeticholic acid; PK, pharmacokinetics.
FIGURE 1 Combined study analyses: Steady-­ state dose-­ normalized plasma or liver total OCA exposure by fibrosis stage. (A) Plasma data are from Study 747-­ 117 and Study 747-­ 118 main study. (B) Liver data are from Study 747-­ 117 and Study 747-­ 118 hepatic PK substudy. Filled circles represent individual subject data. F, fibrosis stage; OCA, obeticholic acid; PK, pharmacokinetics.CC-BY-NC-ND · From the PDF
FIGURE 2 Combined study analyses: Laboratory pharmacodynamic markers percentage change from baseline to Month 1 for control subjects, subjects with NASH fibrosis or subjects with NASH cirrhosis. *The upper end of the error bar, the ALP 25-­ mg cirrhosis group (109%) is not shown. **The lower end of the error bar, the total bilirubin 10 mg control group (-76%), is not shown. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; F, fibrosis stage; GGT, gamma-­ glutamyltransferase; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis.
FIGURE 2 Combined study analyses: Laboratory pharmacodynamic markers percentage change from baseline to Month 1 for control subjects, subjects with NASH fibrosis or subjects with NASH cirrhosis. *The upper end of the error bar, the ALP 25-­ mg cirrhosis group (109%) is not shown. **The lower end of the error bar, the total bilirubin 10 mg control group (-76%), is not shown. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; F, fibrosis stage; GGT, gamma-­ glutamyltransferase; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 23

Metadata

Authors
Alkhouri, N., LaCerte, C., Edwards, J., Poordad, F., Lawitz, E., Lee, L., Karan, S., Sawhney, S., Erickson, M., MacConell, L., Zaru, L., Chen, J., & Campagna, J.
Affiliations
  • The Texas Liver Institute University of Texas Health San Antonio San Antonio Texas USA
  • Intercept Pharmaceuticals, Inc. San Diego California USA
  • Intercept Pharmaceuticals, Inc. Morristown New Jersey USA
Venue
Liver International
Publisher
Wiley
Published
2024-01-31
Volume
44
Issue
4
Pages
966-978
ISSN
  • 1478-3223
  • 1478-3231
Cited by
23
References
19
Language
en
Funders
Intercept Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. https://app.cochat.ai/papers/10.1111/liv.15816
The paper
Alkhouri, N., LaCerte, C., Edwards, J., Poordad, F., Lawitz, E., Lee, L., Karan, S., Sawhney, S., Erickson, M., MacConell, L., Zaru, L., Chen, J., & Campagna, J. (2024). Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver International. https://doi.org/10.1111/liv.15816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.